Overview

Pharmacokinetics in End Stage Renal Disease Patients

Status:
Completed
Trial end date:
2020-07-10
Target enrollment:
Participant gender:
Summary
The study is a multicentre, open label, phase I, two arms study to compare pharmacokinetic of firibastat after a single oral dose of firibastat 500 mg in fourteen healthy male volunteers and in fourteen End Stage Renal Disease (ESRD) patients not yet in dialysis.
Phase:
Phase 1
Details
Lead Sponsor:
Quantum Genomics SA
Collaborator:
Eurofins Optimed
Treatments:
Firibastat